| |
| |
|
| Insider
Information: |
Church Kevin |
| Relationship: |
|
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
80,256 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
80,256 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Athira Pharma, Inc. |
ATHA |
|
2024-01-05 |
80,256 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
19 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ATHA |
Athira Pharma, Inc. |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-01-05 |
4/A |
S |
$2.91 |
$7,019 |
D/D |
(2,412) |
80,256 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-01-04 |
4/A |
A |
$0.00 |
$0 |
D/D |
10,000 |
82,668 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Chief Scientific Officer |
• – – |
2023-11-20 |
4 |
A |
$1.34 |
$4,552 |
D/D |
3,397 |
72,668 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Chief Scientific Officer |
• – – |
2023-05-18 |
4 |
A |
$2.41 |
$1,950 |
D/D |
809 |
69,271 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Chief Scientific Officer |
• – – |
2023-03-24 |
4 |
OE |
$1.35 |
$8,654 |
D/D |
6,410 |
68,462 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Chief Scientific Officer |
• – – |
2023-01-05 |
4 |
S |
$2.91 |
$7,019 |
D/D |
(2,412) |
80,256 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Chief Scientific Officer |
• – – |
2023-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
82,668 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Executive VP, Research |
• – – |
2022-11-18 |
4 |
A |
$2.74 |
$1,800 |
D/D |
657 |
62,052 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Executive VP, Research |
• – – |
2022-10-28 |
4 |
OE |
$1.35 |
$4,995 |
D/D |
3,700 |
61,395 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Executive VP, Research |
• – – |
2022-06-23 |
4 |
S |
$2.69 |
$7,032 |
D/D |
(2,614) |
57,695 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Executive VP, Research |
• – – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
60,309 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Executive VP, Research |
• – – |
2022-06-08 |
4 |
OE |
$1.35 |
$3,375 |
D/D |
2,500 |
50,309 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Executive VP, Research |
• – – |
2022-05-18 |
4 |
A |
$7.06 |
$1,716 |
D/D |
243 |
47,809 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Executive VP, Research |
• – – |
2022-02-18 |
4 |
OE |
$1.19 |
$3,751 |
D/D |
3,152 |
47,566 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Executive VP, Research |
• – – |
2021-11-18 |
4 |
A |
$12.51 |
$1,201 |
D/D |
96 |
44,414 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Vice President of Discovery |
• – – |
2021-06-08 |
4/A |
OE |
$1.04 |
$3,278 |
D/D |
3,152 |
44,318 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Vice President of Discovery |
• – – |
2021-06-08 |
4 |
OE |
$1.04 |
$3,278 |
D/D |
3,152 |
44,133 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Vice President of Discovery |
• – – |
2021-05-18 |
4/A |
A |
$14.45 |
$2,673 |
D/D |
185 |
41,166 |
0 |
- |
|
| ATHA |
Athira Pharma, Inc. |
Vice President of DiscoveryOff |
• – – |
2020-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
40,981 |
|
- |
|
19 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
